$167 SKHY—are you looking to bottom-buy or cut loss?

First, look at the surface: a roller-coaster market, where both bulls and bears get crushed.

Listed on July 10 at a $149 price, it opened at $170. On July 14, Barclays’ first coverage set a $330 target; that day ADR surged 27% to $193.92. On July 15 it then fell 9% to close at $176.46. Yesterday its low was slammed to $149.74. In 11 days—$170 → $194 → $176 → $150 → $167—more wild than a cheap knockoff coin.

First thing: a 51% premium—are the market crazy or are you?

After SKHY listed, the price gap with the original Korean stock (SKHX) once skyrocketed to 51%. Same company’s product—buying it in the U.S. costs about half again versus buying in Korea.

Sounds absurd? But here’s the reason—no arbitrage channel is open. The ADR issuance is only less than 3% of total shares. U.S. institutional demand exploded, but supply can’t expand. On Hyperliquid, SKHX (the original stock) long positions pay a funding rate of +0.10% per hour, while SKHY (ADR) short positions actually receive money—meaning the market is using real money to bet that the premium will narrow.

Second thing: HBM capacity sold out until 2027, yet you’re still watching the K-line?

SK hynix has clearly stated: all HBM for 2026 has been sold out. UBS expects HBM demand in 2026 to grow 90% year-over-year, and then rise another 77% in 2027. In April, Samsung’s memory division head warned that “serious shortages will persist at least through 2027.”

SK hynix’s HBM market share is 58%, far ahead of Micron and Samsung, each at 21%. Bernstein projects Q2 gross margin will reach 91%.

Third thing: Barclays calls for a double, and Wall Street goes all-in bullish

On July 14, Barclays initiated coverage on SKHY and set a $330 target price—implying a 117% upside versus $152 at the time. Analysts believe the supply shortage will further worsen in 2027.

Stocktwits sentiment is “extremely bullish.” Two analysts have a unanimous “Buy” rating, with an average 12-month target price of $342.5.

Bull vs bear—you decide

One side says:

HBM market share 58%, absolute AI memory leader

All 2026 capacity sold out, supply-demand gap of 50%-60%

Barclays $330 target, Wall Street consensus bullish

Korean original stock up over 6.7% on July 21, while U.S. memory chip stocks all surge

The other side says:

ADR and Korean shares still have a 15.5% premium

Only 11 days since listing; price moved from 150 to 195 to 167

The conversion channel between the original shares and ADR may open on July 29

If the premium narrows, the ADR could face additional sell pressure

Key levels

Resistance overhead: 170-175 (near-term pressure) → 180+ → 194 (all-time high)

Support below: 160-162 → 150 (IPO pricing + key psychological level)

For short-term traders:

Wait for a pullback to 160-162 to test a small long position; stop loss at 150; first target 170-175.

For swing traders:

Wait until the daily close holds above 175 before adding on the right side; target 200-250. Watch how the premium changes after the conversion channel opens on July 29—if the premium narrows quickly but the price doesn’t drop, it means buy pressure is strong enough.

For long-term believers:

DCA in batches below 160. Barclays target is $330; analysts’ average target is $342. With SKHY now at $167, there’s still a potential doubling versus institutional target prices. The AI memory super cycle isn’t hype—it’s capacity data turned into certainty written on paper.

SKHY now is like Nvidia in 2020—

99% of people think “it’s up too much and it’s going to crash.” Then the AI wave came, and it went from $60 to $1,000. #GUSD年化升至3.8% #ETH突破1900美元 #夏日创作营 $BTC $NVDA $SKHY